
Unlocking the Potential: New Data from BROOKLYN Clinical Trial of Obicetrapib for Heterozygous Familial Hypercholesterolemia Presented at AHA Conference by NewAmsterdam Pharma
NewAmsterdam Pharma Reports Positive Results from Phase 3 Trial of Obicetrapib Key Findings: Met Primary Endpoint: The Phase 3 BROOKLYN clinical trial of obicetrapib showed a significant reduction in LDL-C levels compared to placebo. The mean reduction was 36.3% at day 84 and 41.5% at day 365. Lp(a) Reduction: Patients in the trial also experienced…